Introduction {#Sec1}
============

Attention-deficit/hyperactivity disorder (ADHD) is characterized by inattention, impulsivity, and hyperactivity and is associated with other psychiatric comorbidities (Pliszka [@CR17]; Spencer [@CR21]). Patients are at a higher risk of cigarette smoking, substance abuse (Daley [@CR7]; Vansickel et al. [@CR24]), more traffic accidents (Barkley [@CR3]; Weiss et al. [@CR26]), and criminality (Klein and Mannuzza [@CR12]). Adverse consequences persist through adolescence into adulthood, including academic impairment, social dysfunction, poor self-esteem (Biederman et al. [@CR4]), and increased rates of suicide (Barbaresi et al. [@CR2]). Thus, the burden of illness associated with ADHD is high for affected individuals, their families, and society (Leibson and Long [@CR13]).

Current treatments for ADHD include social, psychological, and behavioral interventions and pharmacotherapy. The efficacy of pharmacotherapy for ADHD has been investigated in well-documented, short-term studies (Biederman et al. [@CR4]; Perwien et al. [@CR16]). An important question is whether there is a continued value of ADHD pharmacotherapy treatment for subjects who had an initial clinical response. Children and adolescents who responded to open-label atomoxetine treatment maintained their responses for up to 18 months (Michelson et al. [@CR14]; Buitelaar et al. [@CR5]). Maintenance of response to atomoxetine in adults for up to 6 months has also been demonstrated (Upadhyaya et al. [@CR23]).

Most research on the efficacy of ADHD treatments has been conducted within a clinical trial setting in which subject eligibility is restricted by a large set of inclusion and exclusion criteria. In clinical practice, however, the subject population receiving ADHD medications has a wider array of clinical comorbidities than allowed in most clinical trials. Subjects may be prescribed various types of treatment concomitantly, and these treatments may change over time. Thus, it would seem that real-world outcomes would be of considerable interest, but few naturalistic/observational studies have been conducted in pediatric subjects with ADHD.

The Attention-Deficit/Hyperactivity Disorder Observational Research in Europe (ADORE) study, a 24-month, observational study of approximately 1500 children and adolescents in 10 European countries, analyzed long-term treatment patterns (pharmacotherapy, psychotherapy, combination of both, or no intervention) for ADHD and the associated health outcomes for subjects following their diagnosis and first treatment in European naturalistic practice settings (Preuss et al. [@CR18]). Subjects in the ADORE pharmacotherapy treatment groups showed greater improvement than those with nonpharmacotherapy. This finding was similar to that of the Multimodal Treatment Study of ADHD (MTA) (Jensen et al. [@CR11]), a randomized clinical study aimed at comparing the effects of medication management, behavior therapy, a combination of medication and behavior therapies, and usual community care over a 14-month period in the USA (The MTA Cooperative Group [@CR22]), with noninterventional follow-ups at 3 and 8 years (Jensen et al. [@CR11]; Molina et al. [@CR15]). Neither the MTA nor the ADORE study assessed the changes in symptomatology after response to treatment; rather, the focus of these studies was to follow-up with subjects after their initial treatment to determine whether that treatment was effective or ineffective. The AUTOR study was designed to augment the findings of earlier maintenance clinical trials (Gillberg et al. [@CR10]; Michelson et al. [@CR14]; Buitelaar et al. [@CR5]) by characterizing longer-term treatment patterns among pharmacotherapy responders and factors associated with loss of response in the clinical practice setting across Europe.

The AUTOR study is a longitudinal, observational, naturalistic study conducted in subjects from 6 to 17 years old who are diagnosed with ADHD. The primary objective was to identify the factors associated with an increase in ADHD symptom severity during a 2-year follow-up period in subjects who were responders and were stable on their initial pharmacotherapy. Secondary objectives related to effectiveness and tolerability were to describe the factors associated with a decrease in ADHD symptom severity, quality of life (QoL) changes, treatment patterns, factors associated with relapse, factors associated with stability, tolerability, and the duration of treatment effect during the day associated with different pharmacotherapies.

Materials and methods {#Sec2}
=====================

As the primary objective, characterizing factors associated with worsening in ADHD symptoms, was associated with a binary endpoint of worsening or no worsening, the study protocol approximated a sample size of 900 patients using a two-sided Chi-square test at a 5 % significance level in order to have a 80 % power to detect a difference between group 1 proportion p1 = 0.5 and group 2 proportion p2 = 0.59. Slower than expected enrollment resulted in 704 patients in the analysis set, causing only a slight increase in the minimum difference that could be detected between the two group proportions (p1 = 0.5 and p2 = 0.6).

Subjects {#Sec3}
--------

Physicians enrolled patients aged 6--17 years old who had been diagnosed with ADHD and who had responded to their first and current pharmacotherapy treatment for 3--8 months. Clinical responders were identified as having a Clinical Global Impression-ADHD-Severity (CGI-ADHD-S) score of mild or lower (CGI-ADHD-S ≤ 3 at study entry) and a Clinical Global Impression-ADHD-Improvement score (CGI-ADHD-I) of much improved or very much improved (CGI-ADHD-I = 1 or 2) (Arnold et al. [@CR1]) at the baseline observation compared to the time of treatment initiation. Subjects were excluded if they had, in the clinical judgment of the investigator, a pervasive developmental disorder or were already participating in another treatment study.

The requirement for treatment stability at study entry increased the naturalistic character of the trial by ensuring that treatment patterns were not altered due to participation in the study. During AUTOR, subjects were allowed to take any commercially available medication (including combination therapy) or nonpharmacotherapy for the treatment of ADHD; ADHD treatment could be discontinued or changed at any time, and subjects were followed in the study, regardless of changes or discontinuation of their original ADHD treatment.

Subjects were informed as to the risks and benefits of trial participation; their parents gave written consent and they provided written assent for the use of their data, as required by local regulations. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was consistent with good clinical practices and applicable local laws and regulations.

Procedure {#Sec4}
---------

Data were collected at naturally occurring visits for the subjects, according to regular practice at the study site; these visits were assigned to the closest of the following observation windows: 0, (baseline), 3, 6, 9, 12, 18, and 24 months (from baseline), ± 6 weeks. Apart from baseline confirmation of eligibility and capture of subject/family information and demographics, all other assessments were performed at each visit.

Symptom severity was measured with the CGI-ADHD-S and the ADHD Rating Scale-IV-Parent Version-Investigator-completed (ADHDRS). ADHD symptom severity worsening was defined as a ≥2-point increase from baseline in CGI-ADHD-S score. A two-point worsening on CGI-ADHD-S was included to identify clinically meaningful relapse in the relapse prevention study of atomoxetine (Michelson et al. [@CR14]) and a lisdexamphetamine trial (Coghill et al. [@CR6]). A decrease in ADHD severity was defined as a ≥2-point decrease in the CGI-ADHD-S from one of the follow-up observations to any of the subsequent observations.

Information on the use of pharmacotherapy and other treatments for ADHD was collected at each visit. Pharmacotherapy treatment classes at baseline were a priori defined for analysis as stimulant, atomoxetine, other, and combination. The combination class comprised subjects taking more than one pharmacotherapy class. Subjects in any treatment class could receive nonpharmacotherapy sessions. A change in pharmacotherapy was defined as moving from one class to another or changing to only nonpharmacotherapy treatment. Discontinuation from therapy was defined as no pharmacotherapy and no nonpharmacotherapy for at least 4 weeks.

QoL changes over the 2-year period were measured by the Child Health and Illness Profile, Child Edition-Parent Report Form (CHIP-CE PRF) (Riley et al. [@CR19], [@CR20]).

Four different definitions of relapse were used: (1) increase of 50 % or greater on the ADHDRS total score and an increase in the CGI-ADHD-S score of at least 2 points, (2) increase of at least 50 % on the ADHDRS total score from the baseline, (3) a CGI-ADHD-S score of at least markedly ill (≥5) at any post-baseline assessment, and (4) a minimum of a 2-point increase on the CGI-ADHD-S from baseline over 2 consecutive post-baseline assessments. Stability was defined as CGI-ADHD-S of "mild" or lower (≤3) over the entire 2-year period. Relapse definition 1 was used in the pivotal maintenance of response study of atomoxetine (Michelson et al. [@CR14]) and a recent lisdexamphetamine maintenance of response trial (Coghill et al. [@CR6]). Relapse definition 2 included the ADHDRS symptom assessment only, and relapse definition 4 required a repeated observation of worsening to flag relapse.

Duration of treatment effect during the day associated with different pharmacotherapies was measured by the Global Impression of Perceived Difficulties (GIPD) scale (Wehmeier et al. [@CR25]).

Statistical analysis {#Sec5}
--------------------

### General considerations {#Sec6}

Analyses were exploratory. Two baseline treatment classes (stimulant and atomoxetine) were compared with respect to their effect on worsening of ADHD severity and other secondary outcome/tolerability measures. All statistical analyses were pre-specified in a Statistical Analysis Plan that was approved before database lock. All statistical analyses were performed using SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA). No corrections were made for multiple comparisons.

### Demographics and treatment compliance and patterns {#Sec7}

Descriptive statistics were used to summarize subject characteristics, total daily dose by baseline pharmacological treatment group and by time point, compliance by baseline pharmacological treatment group, number of sessions per month by baseline nonpharmacological treatment and time point, and time to first change/switch/discontinuation of therapy. The Kaplan--Meier method was used to estimate the survival curves for time to first change/switch/discontinuation of therapy and comparison between treatment groups were conducted by a 2-sided log-rank test. Subjects discontinuing the study without discontinuing treatment were considered censored at the time of exiting the study.

### Primary outcome measure {#Sec8}

Multivariate logistic regression was used to identify factors associated with worsening in ADHD severity. A patient was considered to have a worsening in ADHD severity if a minimum of two points increase in the CGI-ADHD-S score (vs. baseline CGI-ADHD-S score) was observed at any of the subsequent follow-up observations. The set of covariates are listed in Table [1](#Tab1){ref-type="table"}. Covariates that were noncorrelated (*r* \< 0.7) and statistically significant in univariate logistic regression models (*p* \< 0.10) were included in the full multivariate logistic models. The analysis plan allowed for treatment to be included as a time-varying covariate only if \>25 % of patients switched their baseline medication; however, the proportion of patients switching treatments was much lower so treatment was not included as a time-varying covariate. Treatment compliance was included as a time-varying covariate in the multivariate models; however, the addition of this covariate did not change the model estimates and was dropped from the final model. In addition, propensity scores (PS), estimated using multivariable logistic regression, were included in the models as additional covariates to adjust for the probability of receiving a specific treatment given the subject gender, age, ADHD subtype, family history of ADHD, substance use, psychiatric comorbidities and resource utilization baseline variables. Logistic models with and without PS covariates were estimated. For the final multivariable model, Type III *p* values and adjusted odds ratios comparing each level against an arbitrary baseline reference level and associated 95 % CI were calculated.Table 1Covariates considered in the logistic regression modeling process for primary and secondary endpointsIndependent variablesCategoriesReference levelBaseline covariates GenderMale versus femaleFemale Age5--12 versus 13--1813--18 years ADHD subtypeHyperactive/impulsive or combined, inattentiveInattentive Family history of ADHDImmediate family, extended family, no family historyNo family history Substance useYes (if smoked, used alcohol, or used illegal drugs) versus no substance useNo substance use Psychiatric comorbiditiesCurrent presence of Tourette's Disorder, tics, anxiety, depression, conduct disorder, oppositional defiant disorder, bipolar disorder, or psychosis versus no current presence of 1 of these conditionsNo current presence of these comorbidities Total number of contacts to all healthcare providersContinuousN/A OriginWest Asian, East Asian, Hispanic, Black or African-American, WhiteWhite Family settingChild lives with single biological parent, guardian, biological parents separately, both biological parents, otherOther Number of siblingsContinuousN/A Parental work statusWorking for pay full-time, part-time work, unemployed, keeping houseWorking for pay full-time PsychoeducationYes, noNo ADHDRS total scoreTreated as continuousN/A Parental occupationElementary occupations; managers and senior officials; process, plant and machine operatives; sales and customer service; caring, leisure and other personal service; skilled trades; administrative and secretarial; associate professional and technical occupationsManagers and senior officials School outcomes (in 3 months prior to study entry)Not in school during the past 3 months, suspended from school, expelled from school, or requested to change to a special need school; Some exclusion from school lessons or in a special education program; or manageable in a classroom environmentManageable in a classroom environment Propensity scoreContinuousN/A TreatmentStimulant, atomoxetineAtomoxetineTime-varying covariates ComplianceNever, Always, Occasionally, Some of the Time, Most of the TimeAlways*N/A* nonapplicable, *vs.* versus

### Secondary outcomes {#Sec9}

Mixed models for repeated measures (MMRM) were used to estimate adjusted differences between stimulant and atomoxetine baseline treatments in relation to changes from baseline for GIPD total scores and items and the CHIP-CE PRF standardized total, domain, and subdomain scores. The MMRMs contained baseline treatment, visit, baseline treatment-by-visit and PS and baseline treatment-by-PS interactions as independent variables and used an unstructured covariance matrix to model the between-subjects and within-subjects errors. Other covariates considered in the model were age, gender, ADHD subtype, family history of ADHD, drug consumption, psychiatric comorbidities, score at baseline, compliance at baseline, tolerability at baseline, treatment satisfaction at baseline, school outcomes at baseline, baseline bullying, and total number of contacts to healthcare providers at baseline. Of these covariates, only covariates found to be significant (*p* \< 0.10) in a first-step model (including baseline treatment, visit, baseline treatment-by-visit and PS, baseline treatment-by-PS interactions, and the covariate of interest) were retained in the final multivariable model. Multivariate logistic regression models were used to estimate adjusted odds ratios for variables associated with relapse and stability. The covariates were the same as those used in the analysis of the primary outcome variable (Table [1](#Tab1){ref-type="table"}). Logistic regression models, with and without PS, and with and without treatment compliance as time-varying covariates, were estimated.

### Tolerability {#Sec10}

The number and percentage of subjects with solicited AEs were calculated for each visit within the treatment class at that visit. The effect of baseline treatment on AEs was assessed with a logistic regression model for repeated measures using a population-averaged GEE approach. GEE models included baseline treatment, visit, treatment-by-visit interaction, propensity score, and treatment-by-PS interactions as independent variables. An unstructured covariance matrix was used to model the between and within subject errors. For each AE, adjusted odds ratios between treatments at each visit and averaged over all visits were estimated.

Results {#Sec11}
=======

Disposition, demographics, and baseline characteristics {#Sec12}
-------------------------------------------------------

The AUTOR study was conducted at 74 study centers in Denmark, Greece, Italy, Netherlands, Romania, Slovenia, Sweden, and the UK. Subject enrollment began September 2008 and completed in February 2013. Practice settings (93 % urban) were 4 % inpatient, 47 % outpatient, and 49 % a combination of both and were 8 % private, 68 % public, and 24 % a combination of both.

The majority (86 %) of investigators were child psychiatrists, and the remainder were neurologists, child neurologists, and pediatricians with an average duration of practice of 25 years. Of the 801 subjects who entered the study, 704 met entry criteria and comprised the analysis set. At baseline, 704 subjects were stable on and responsive to the following medications: stimulants (*N* = 302 \[48 % methylphenidate and 53 % methylphenidate long-acting\]), atomoxetine (*N* = 395), other pharmacotherapies (*N* = 5 \[60 % antipsychotics and 40 % other), or a drug combination (*N* = 2 \[100 % methylphenidate long-acting and atomoxetine\]) (Table [2](#Tab2){ref-type="table"}).Table 2Patient flow from baseline to month eighteenAnalysis visitStimulantAtomoxetineBaseline*N* = 302*N* = 3953 Months Discontinued at previous visits105 Pharmacotherapy nonstimulantN/A376 Pharmacotherapy stimulant272N/A Drug combination11 Present at further visits, did not attend current visit19136 Months Discontinued at previous visits1418 Pharmacotherapy nonstimulant2342 Pharmacotherapy stimulant2563 Drug combination12 Nonpharmacotherapy14 No treatment for primary study condition33 Present at further visits, did not attend current visit25239 Months Discontinued at previous visits2226 Pharmacotherapy nonstimulant2326 Pharmacotherapy stimulant2317 Drug combinationN/A1 Nonpharmacotherapy27 No treatment for primary study condition711 Present at further visits, did not attend current visit3717 Discontinued after month 61N/A12 Months Discontinued at previous visits3237 Pharmacotherapy nonstimulant8309 Pharmacotherapy stimulant23112 Drug combination25 Nonpharmacotherapy38 No treatment for primary study condition814 Present at further visits, did not attend current visit169 Discontinued after month 61N/A Discontinued after month 9N/A1 Completed at previous visits1N/A18 Months Discontinued at previous visits4442 Pharmacotherapy nonstimulant8293 Pharmacotherapy stimulant21715 Drug combination23 Nonpharmacotherapy312 No treatment for primary study condition920 Present at further visits, did not attend current visit179 Discontinued after month 61N/A Discontinued after month 9N/A1 Completed at previous visits1N/A24 Months Discontinued at previous visits6762 Pharmacotherapy nonstimulant9265 Pharmacotherapy stimulant20617 Drug combination16 Nonpharmacotherapy312 No treatment for primary study condition331 Discontinued after month 61N/A Discontinued after month 9N/A1 Discontinued after month 184N/A Completed at previous visits81*N* number of subjects, *N/A* not applicable

Of the 704 subjects in the study, the majority were Caucasian (98.9 %) and male (81.5 %). Nearly 80 % of the subjects completed the 2-year study. Table [3](#Tab3){ref-type="table"} summarizes the physical characteristics, comorbidities, prior treatment duration, and disposition of the sample. Figure [1](#Fig1){ref-type="fig"} summarizes the subjects by country. The majority of subjects were recruited from Italy, Romania, and Greece, and the pattern of allocation to treatment reflects the timing of medication availability in those regions.Table 3Physical characteristics, psychiatric comorbid conditions, disposition, and prior treatment durationBaseline treatment groupStimulant\
*N* = 302Atomoxetine\
*N* = 395Physical characteristics, mean (SD) Age10.9 (2.6)10.6 (2.8) Height145.0 (16.6)143.1 (17.2) Weight40.1 (15.2)39.7 (15.8) BMI18.5 (3.6)18.7 (3.9)ADHD subtype Predominantly inattentive, *n* (%)42 (13.9)62 (15.7) Predominantly hyperactive impulsive, *n* (%)21 (7.0)40 (10.1) Combined, *n* (%)239 (79.1)293 (74.2)ADHD severity CGI-ADHD-S, mean (SD)2.6 (0.50)2.5 (0.60) ADHDRS total score, mean (SD)25.1 (11.40)22.8 (11.81) ADHDRS Inattentive Subscale, mean (SD)13.3 (6.07)12.5 (6.00) ADHDRS Hyperactivity-Impulsivity Subscale, mean (SD)11.8 (6.28)10.3 (6.82)Psychiatric comorbidities, *n* (%) Anxiety24 (7.9 %)82 (20.9 %) Depression10 (3.3 %)19 (4.8 %) Conduct disorder31 (10.3 %)43 (10.9 %) Oppositional defiant disorder88 (29.1 %)108 (27.5 %) Tourette's syndrome1 (0.3 %)1 (0.3 %) Tics13 (4.3 %)22 (5.6 %) Coordination problems28 (9.3 %)28 (7.1 %) Dyslexia51 (16.9 %)89 (22.6 %) Other learning disorders90 (29.8 %)137 (34.9 %) Bipolar disorder1 (0.3 %)0 (0.0 %) Psychosis1 (0.3 %)0 (0.0 %) Obsessive compulsive disorder2 (0.7 %)3 (0.8 %)Subject disposition, *n* (%) Completed223 (73.8 %)325 (82.3 %) Discontinued79 (26.2 %)70 (17.7 %) Caregiver decision27 (8.9 %)41 (10.4 %) Loss to follow-up26 (8.6 %)15 (3.8 %) Subject decision15 (5.0 %)12 (3.0 %) Physician decision11 (3.6 %)2 (0.5 %) Duration of baseline treatment (months), mean (SD)4.9 (1.5)5.0 (1.5)*N* number of subjects, *n* number of affected subjects, *SD* standard deviationFig. 1Countries participating in AUTOR

Treatment compliance and patterns {#Sec13}
---------------------------------

Treatment compliance was estimated by clinical staff at each visit by selecting for how they took medication---never, occasionally do, some of the time, most of the time, and always. Treatment compliance was comparable across baseline treatment groups, and it decreased throughout the study with the highest compliance observed at baseline (74.0 % always, 21.6 % most of the time, 2.3 % some of the time, 1.2 % occasionally do, and 0.9 % never) and the lowest compliance observed at Month 24 (65.1 % always, 26.1 % most of the time, 5.6 % some of the time, 1.8 % occasionally do, and 1.4 % never). The average total daily dose of medication showed no to minimal change over the 2 years of treatment for subjects who remained on monotherapy. Average total daily doses at baseline and at 24 months are shown in Table [4](#Tab4){ref-type="table"}.Table 4Summary of pharmacological and nonpharmacological treatment-by-visit and treatmentBaseline24 MonthsStimulant\
*N* = 305Atomoxetine\
*N* = 395Stimulant\
*N* = 244Atomoxetine\
*N* = 274Average total daily dose, mg/kg, mean (SD)0.5 (0.2)^a^, 0.8 (0.3)^b^1.0 (0.3)0.5 (0.3)^a^, 0.9 (0.3)^b^1.1 (0.3)Average total daily dose, mg, mean (SD)19.5 (9.7)^a^, 31.2 (12.1)^b^37.7 (16.7)20.3 (10.6)^a^, 32.2 (11.9)^b^39.9 (17.0)At least one nonpharmacological treatment, *n* (%)91 (30.1)156 (39.5)88 (29.1)158 (40.0)Psychoeducation programs, *n* (%)36 (11.9)52 (13.2)37 (12.3)53 (13.4)Counseling, *n* (%)37 (12.3)51 (12.9)30 (9.9)52 (13.2)Cognitive behavioral therapy, *n* (%)20 (6.6)29 (7.3)23 (7.6)36 (9.1)Family therapy, *n* (%)2 (0.7)11 (2.8)2 (0.7)17 (4.3)Psychodynamic therapy, *n* (%)1 (0.3)3 (0.8)7 (2.3)10 (2.5)Educational interventions in school, *n* (%)21 (7.0)24 (6.1)21 (7.0)35 (8.9)Speech therapy, *n* (%)7 (2.3)20 (5.1)7 (2.3)26 (6.6)Occupational therapy, *n* (%)2 (0.7)3 (0.8)2 (0.7)5 (1.3)Relaxation techniques, *n* (%)0 (0.0)2 (0.5)0 (0.0)2 (0.5)Hypnosis, *n* (%)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Psychomotor/physiotherapy, *n* (%)6 (2.0)13 (3.3)7 (2.3)10 (2.5)EEG biofeedback, *n* (%)1 (0.3)0 (0.0)0 (0.0)0 (0.0)Herbal/homeopathy, *n* (%)0 (0.0)2 (0.5)0 (0.0)1 (0.3)Diet exclusion, *n* (%)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Diet supplement, *n* (%)1 (0.3)0 (0.0)1 (0.3)0 (0.0)Other, *n* (%)2 (0.7)8 (2.0)3 (1.0)9 (2.3)*EEG* electroencephalography, *n* number of affected subjects, *SD* standard deviation^a^Methylphenidate^b^Methylphenidate long-acting

Fewer subjects in the stimulant group at baseline changed therapy (7.9 vs. 11.4 %), discontinued treatment (13.2 vs. 14.9 %), or had a change of dose (17.9 vs. 23.3 %) versus subjects on atomoxetine at baseline. The log-rank test showed that there was no statistical difference between the treatments regarding time to any of these events. Time until 5 % of the population had an event is reported as the median time to event was not defined. As determined by the Kaplan--Meier survival curves, the estimated length in days and 95 % CI until 5 % of the population had an event for stimulant-treated versus atomoxetine-treated subjects for time to first change of therapy (Fig. [2](#Fig2){ref-type="fig"}) was 283.6 \[153.8--565.3\] days versus 269.6 \[194.7--327.6\] days, respectively. The estimated length in days and 95 % CI until 5 % of the population had an event for stimulant-treated versus atomoxetine-treated subjects for time to first treatment discontinuation (Fig. [3](#Fig3){ref-type="fig"}) was 194.7 \[92.9--286.6\] days versus 166.8 \[113.9--244.7\] days. The estimated length in days and 95 % CI until 5 % of the population had an event for stimulant-treated versus atomoxetine-treated subjects for time to first dose change (Fig. [4](#Fig4){ref-type="fig"}) was 89.9 \[76.9--105.9\] days versus 93.9 \[81.9--126.8\] days, respectively.Fig. 2Kaplan--Meier plot for time to first change of therapyFig. 3Kaplan--Meier plot for time to first treatment discontinuationFig. 4Kaplan--Meier plot for time to first dose change

Few subjects (15 \[2.1 %\] at 24 months) switched to only receive nonpharmacotherapy during the study; however, over a third of subjects were receiving some form of nonpharmacotherapy at study entry. There was little change in nonpharmacological treatment participation over the course of 24 months (Table [4](#Tab4){ref-type="table"}).

Primary outcome measure {#Sec14}
-----------------------

Figure [5](#Fig5){ref-type="fig"} presents the results from the multivariate logistic model estimated without PS and/or time-varying covariates. School outcome was statistically significant (Type III *p* \< 0.001), with the odds of an increase in ADHD symptoms severity being significantly greater for subjects who had some exclusion from school lessons and/or were in a special education program than for subjects who were manageable in a classroom environment (odds ratio \[95 % CI\]; 2.7 \[1.5--4.8\]; *p* \< 0.001). The odds of an increase in ADHD symptom severity were significantly greater in subjects who were not in school during the past 3 months, who were suspended from school, who were expelled from school, and/or who were requested to change to a special need school than in subjects who were manageable in a classroom environment at baseline (odds ratio \[95 % CI\]; 5.0 \[1.4--18.2\]; *p* = 0.015). Baseline parental occupation was also statistically significant (Type III *p* = 0.003) overall; however, none of the specific pairwise comparisons between parental occupations to the arbitrary reference group (managers and senior officials) were statistically significant. The odds of an increase in ADHD symptom severity were also significantly greater for subjects who received psychoeducation at baseline than for subjects who did not receive it at baseline (odds ratio \[95 % CI\]; 2.2 \[1.3--3.7\]; *p* = 0.004).Fig. 5Factors associated with an increase in symptom severity in subjects with attention-deficit/hyperactivity disorder (from a multivariate logistic regression model). For each factor, adjusted odds ratios comparing each level against the baseline reference level and associated 95 % CI and Type III *p* values are presented. Additionally, for factors with more than 2 levels, corresponding homogeneity Type III *p* values are also shown. Estimates from the logistic regression model that included propensity scores and/or treatment compliance as time-varying covariates as additional adjusting factors were similar to the models without these additional adjustments. Abbreviations: *0* school outcome of manageable in a classroom environment; *1* school outcome of some exclusion from school lessons and/or in a special education program, *2* school outcome of not in school during the past 3 months, suspended from school, expelled from school, and/or requested to change to a special need school, *CI* confidence interval, *LL* lower limit, *UL* upper limit, *vs.* versus

Secondary outcome measures {#Sec15}
--------------------------

For the secondary outcome measures, like the primary outcome analysis, the estimates from the logistic regression model including additional PS covariates and/or time-varying covariates were similar to the models without PS and without time-varying covariates. Therefore, results from the model without a PS and without time-varying covariates are reported. Factors associated with a decrease in ADHD symptom severity showed a statistically significant effect of parental work status (Type III *p* = 0.001), with the odds of a decrease in ADHD symptom severity being significantly greater for subjects who had parents who worked part-time at baseline than for those who had parents who worked for full-time pay at baseline (odds ratio \[95 % CI\]; 11.7 \[3.4--39. 9\]; *p* \< 0.001).

The MMRM analysis of changes from baseline in CHIP-CE PRF standardized total scores showed a statistically significant baseline treatment-by-visit interaction (Type III *p* \< 0.001). At Months 3, 9, 12, 18, and 24, subjects who entered the study on stimulants had significantly less improvement from baseline in CHIP-CE PRF standardized total scores than subjects who entered the study on atomoxetine (Fig. [6](#Fig6){ref-type="fig"}). The estimates of the adjusted differences (least-square means) between subjects who entered on stimulants and atomoxetine were increasing over time. In particular, the maximum difference between baseline treatment groups was −6.0 (95 % CI −7.9, −4.1) at 24-month post-baseline.Fig. 6Least-squares mean change from baseline in the Child Health and Illness Profile, Child Edition-Parent Report Form total score from the longitudinal mixed-model repeated measures regression. Abbreviations: *CHIP-CE PRF* Child Health and Illness Profile-Child Edition, Parent Report Form, *LS* least squares

Logistic regression models were used to study the association of different risk factors with each of the 4 protocol definitions of relapse (Table [5](#Tab5){ref-type="table"}). The majority of subjects did not relapse at any time during the 2-year study. Higher baseline ADHDRS total score was associated with a decreased probability of relapse for the definitions that included ADHDRS total as a relapse criterion and an increased probability of relapse according to the definition based only on the CGI-ADHD-S. The odds of relapse were significantly greater for subjects who entered the study on stimulants, who had received psychoeducation at baseline, who had a family history of ADHD, or who had a comorbidity. The odds of relapse were significantly increased for subjects not manageable in a classroom environment.Table 5Factors associated with relapse and stability---odds ratios (95 % confidence intervals) and Type III *p* values from multivariate logistic regression models without propensity score adjustment or time-varying covariates includedBaseline treatment groupRelapse (4 definitions)\
OR (95 % CI)Stability\
OR (95 % CI)ADHDRS total increase ≥50 % and CGI--ADHD--S increase ≥2ADHDRS total increase ≥50 %CGI-ADHD-S ≥5CGI-ADHD-S increase ≥2 at 2 or more consecutive post-baseline visitsCGI-ADHD-S ≤3 over the 2-year periodStimAtxStimAtxStimAtxStimAtxStimAtxRelapsed/stable, %4.03.319.913.28.64.68.64.179.085.1Baseline ADHDRS total score**0.9 (0.90, 0.98)** ^**a**^**0.90 (0.88, 0.92)**NI**1.04 (1.01, 1.07)0.98 (0.96--0.998**)Treatment at baseline (stimulant vs. atomoxetine)1.7 (0.7, 3.9)**2.1 (1.3, 3.3)**1.8 (0.9, 3.7)**2.4 (1.2, 4.8)0.5 (0.3--0.8)**Gender (male vs. female)NININI4.15 (0.97, 17.80)0.6 (0.3, 1.1)AgeNININI2.8 (0.8, 9.4)NIPsychoeducation at baseline (yes vs. no)**3.0 (1.3, 7.0)**NI1.9 (0.9, 3.9)**2.4 (1.2, 4.8)0.6 (0.4--0.9)**School outcomes^b^ Type III *p* valueNINI*p* \< 0.0010.065*p* \< 0.001 2 versus 0NINI**14.3 (3.4, 59.0)4.5 (1.3, 16.2)**0.5 (0.1, 1.9) 1 versus 0NINI**5.1 (2.4, 10.8)**1.2 (0.5, 2.5)**0.4 (0.2--0.6)**Family history of ADHD Type III *p* valueNINI0.134NINI Immediate family versus noneNINI**2.3 (1.1, 5.0)**NINI Extended family versus noneNINI2.7 (0.7, 10.7)NINIPsychiatric comorbidity (yes vs. no)NINI**2.3 (1.1, 4.9)**NI0.7 (0.5, 1.1)Family setting at baseline (reference group is "other") Type III *p* valueNI0.066NININI Step parentNI6.6 (0.8, 56.5)NININI Single parentNI**9.7 (1.2, 79.2)**NININI GuardianNI2.3 (0.2, 24.3)NININI Separately with parentsNI2.3 (0.2, 26.2)NININI ParentsNI5.9 (0.8, 45.3)NININIBaseline parental occupation (reference group is "managers and senior officials")NI Type III *p* valueNINI0.174NI\<0.001 Elementary occupationsNINI0.3 (0.1, 2.1)NI3.04 (0.96, 9.58) Process, plant and machine operativesNINI0.5 (0.1, 4.1)NI1.4 (0.4, 5.1) Sales and customer service occupationsNINI1.1 (0.2, 7.8)NI0.7 (0.2, 2.2) Caring, leisure, and other personalNINI0.9 (0.1, 5.6)NI0.8 (0.3, 2.3)Service occupations Skilled trades occupationsNINI0.3 (0.03, 3.96)NI0.6 (0.2, 1.9) Administrative and secretarial occupationsNINI0.7 (0.1, 4.3)NI1.0 (0.3, 3.2) Associate professional and technical occupationsNINI2.2 (0.4, 12.4)NI0.4 (0.1, 1.3) Professional occupationsNINI0.6 (0.1, 3.1)NI1.7 (0.6, 4.7)ADHD subtype, origin, substance use, total healthcare provider contacts, number of siblings, parental work status were not significantly associated with any definition of relapse or stability*ADHD* attention-deficit/hyperactivity disorder, *ADHDRS* Attention-Deficit/Hyperactivity Disorder Rating Scale, *Atx* atomoxetine, *CGI*-*ADHD*-*S* Clinical Global Impression-Attention-Deficit/Hyperactivity Disorder-Severity, *CI* confidence interval, *NI* not included (variable not significant in the univariate model and not selected for inclusion in the full multivariate model; treatment was always included in the multivariate models, irrespective of being significant or not in the univariate models), *OR* odds ratio,*vs.* versus^a^Bolded values are statistically significant (*p* \< 0.05)^b^School outcomes were as follows: 2 = if 1 of the following: not in school during the past 3 months, suspended from school, expelled from school, requested to change to a special need school; 1 = if 1 of the following: some exclusion from school lessons, in a special education program; 0 = if manageable in a classroom environment

Factors associated with stability (Table [5](#Tab5){ref-type="table"}) showed a statistically significant effect of baseline school outcome (Type III *p* \< 0.001), with the odds of stability being significantly lower for subjects who had some exclusion from school lessons or were in a special education program at baseline than for those who were manageable in a classroom environment at baseline. In addition, the odds of stability were significantly lower for subjects who entered the study on stimulants versus those who entered on atomoxetine and for subjects who received psychoeducation versus those who did not. The odds of stability decreased by a factor of 0.98 when the baseline ADHDRS total score increased 1 unit, keeping the other variables constant. There was a significant effect of baseline parental occupation in the multivariate model with or without time-varying covariates added (Type III *p* \< 0.001), but the comparison of subjects who had parents in elementary occupations versus those whose parents were managers and senior officials was only statistically significant in the model with time-varying covariates added (odds ratio \[95 % CI\]; 4.2 \[1.3--14.0\]; *p* = 0.019). When the logistic regression model included PS, the results were generally similar to the logistic regression without PS with one exception: The odds of stability estimated with the model that included PS were significantly lower in subjects with at least one psychiatric comorbidity than in subjects without a psychiatric comorbidity (odds ratio \[95 % CI\]; 0.5 \[0.3--0.9\]; *p* = 0.014), whereas the odds ratio for stability was not significant in the model that did not include PS (Table [5](#Tab5){ref-type="table"}).

For the GIPD total score, the adjusted difference between stimulants and atomoxetine averaged over the 2-year period was statistically significant (estimate \[95 % CI\]; 0.3 \[0.1--0.4\]; *p* \< 0.001), with patients who entered the study on stimulants being more likely to have investigator-perceived difficulties (i.e., higher GIPD total scores) than patients who entered on atomoxetine at all post-baseline time points (Month 3 \[LS mean change from baseline stimulant vs. atomoxetine; −0.1 vs. −0.3; *p* = 0.014\]; Month 6 \[−0.2 vs. −0.4; *p* = 0.048\], Month 9 \[−0.2 vs. −0.4; *p* = 0.006\]; Month 12 \[−0.1 vs. −0.4; *p* = 0.005\]; Month 18 \[−0.1 vs. −0.5; *p* \< 0.001\]; and Month 24 \[−0.1 vs. −0.6; *p* \< 0.001\]). Similar results were observed for the estimated averaged difference between stimulants and atomoxetine when the other 3 GIPD questions were analyzed using the MMRM: "Difficulty during school" (Type III *p* \< 0.001), "Difficulty during homework" (Type III *p* \< 0.001), and "Difficulty over the entire day including night" (Type III *p* = 0.010). MMRM estimates for the treatment-by-visit interaction were not statistically significant for the 2 GIPD questions "Difficulty in morning" (Type III *p* = 0.411) and "Difficulty in evening" (Type III *p* = 0.971), indicating a constant difference between treatments at all visits during the 2-year period. The estimated average treatment effect for each of these GIPD questions showed that patients who entered the study on stimulants were more likely to have investigator-perceived difficulties in the morning (estimate \[95 % CI\]; 0.3 \[0.2--0.5\]; *p* \< 0.001) and in the evening (0.3 \[0.1--0.4\]; *p* \< 0.001) than patients who entered on atomoxetine.

Tolerability {#Sec16}
------------

Overall, the percentages of solicited AEs were low and generally decreased throughout the course of the study for subjects who entered the study on stimulants or atomoxetine (Table [6](#Tab6){ref-type="table"}).Table 6Percentage of solicited adverse events that interfered with subjects' functioning or health-related quality of lifeTime point\
Tolerability variableOverall^a^\
*N* (% \[95 % CI\])Stimulant at baseline\
*N* (% \[95 % CI\])Atomoxetine at baseline\
*N* (% \[95 % CI\])Baseline*N* = 704*N* = 302*N* = 395 Abdominal pain6 (0.9 \[0.3--1.8\])3 (1.0 \[0.2--2.9\])3 (0.8 \[0.2--2.2\]) Changes in personality2 (0.3 \[0.0--1.0\])2 (0.7 \[0.1--2.4\])0 Decreased appetite27 (3.8 \[2.5--5.5\])7 (2.3 \[0.9--4.7\])20 (5.1 \[3.1--7.7\]) Fatigue5 (0.7 \[0.2--1.6\])1 (0.3 \[0.0--1.8\])4 (1.0 \[0.3--2.6\]) Headaches9 (1.3 \[0.6--2.4\])3 (1.0 \[0.2--2.9\])6 (1.5 \[0.6--3.3\]) Insomnia14 (2.0 \[1.1--3.3\])4 (1.3 \[0.4--3.4\])10 (2.5 \[1.2--4.6\]) Sleepiness3 (0.4 \[0.1--1.2\])2 (0.7 \[0.1--2.4\])1 (0.3 \[0.0--1.4\])Month 12*N* = 607*N* = 252*N* = 348 Abdominal pain4 (0.7 \[0.2--1.7\])1 (0.4 \[0.0--2.2\])3 (0.9 \[0.2--2.5\]) Changes in personality3 (0.5 \[0.1--1.4\])1 (0.4 \[0.0--2.2\])2 (0.6 \[0.1--2.1\]) Decreased appetite11 (1.8 \[0.9--3.2\])3 (1.2 \[0.2--3.4\])8 (2.3 \[1.0--4.5\]) Fatigue000 Headaches9 (1.5 \[0.7--2.8\])2 (0.8 \[0.1--2.8\])7 (2.0 \[0.8--4.1\]) Insomnia9 (1.5 \[0.7--2.8\])5 (2.0 \[0.6--4.6\])4 (1.1 \[0.3--2.9\]) Sleepiness000Month 24*N* = 559*N* = 222*N* = 331 Abdominal pains1 (0.2 \[0.0--1.0\])01 (0.3 \[0.0--1.7\]) Changes in personality1 (0.2 \[0.0--1.0\])1 (0.5 \[0.0--2.5\])0.0 Decreased appetite3 (0.5 \[0.1--1.6\])1 (0.5 \[0.0--2.5\])2 (0.6 \[0.1--2.2\]) Fatigue000 Headaches2 (0.4 \[0.0--1.3\])1 (0.5 \[0.0--2.5\])1 (0.3 \[0.0--1.7\]) Insomnia4 (0.7 \[0.2--1.8\])2 (0.9 \[0.1--3.2\])2 (0.6 \[0.1--2.2\]) Sleepiness000*CI* confidence interval, *MPH* methylphenidate, *N* number of subjects^a^No solicited adverse events that interfered with subjects functioning or health-related quality of life were reported for treatment categories other pharmacotherapies (*N* = 5 \[60 % antipsychotics and 40 % other), or a drug combination (*N* = 2 \[100 % MPH long-acting and atomoxetine\])

The GEE logistic regression analysis indicated that the treatment-by-visit interactions for abdominal pain, fatigue, and headache were not statistically significant. The estimates of the odds ratios averaged over all visits indicated that patients who received stimulants at baseline were less likely to experience abdominal pain (averaged odds ratio \[95 % CI\]; 0.5 \[0.3--0.7\]; *p* = 0.002); fatigue (averaged odds ratio \[95 % CI\]; 0.4 \[0.2--0.9\]; *p* = 0.018); and headache (averaged odds ratio \[95 % CI\]; 0.4 \[0.3--0.7\]; *p* \< 0.001). The baseline treatment-by-visit interactions were statistically significant for decreased appetite (Type III *p* = 0.05) and insomnia (Type III *p* = 0.017). For decreased appetite, there was a statistical difference in the odds of having decreased appetite only at the 24-month visit, with greater odds for subjects receiving stimulants at baseline (odds ratio \[95 % CI\]; 3.3 \[1.5--7.1\]; *p* = 0.002). For insomnia, a statistically significant difference was observed between baseline treatment groups only at Month 12 with the odds of having insomnia being significantly lower in the group who received stimulants at baseline (odds ratio \[95 % CI\]; 0.5 \[0.3--0.98\]; *p* = 0.044).

Discussion {#Sec17}
==========

This study characterizes factors associated with an increase in ADHD symptom severity during a 2-year follow-up period in subjects who were responders and stable on their first pharmacotherapy. In contrast to the magnitude of switching observed in the ADORE study (Preuss et al. [@CR18]), stability continued for the vast majority of subjects who were stable on their ADHD treatment for 3--8 months. Baseline treatments were maintained, there was minimal switching or changes in dose, and compliance was good. This difference might be due to ADORE being a study of patients newly initiated to treatment, while AUTOR was a study of treatment responders.

School outcome and parental occupation at baseline were identified as factors associated with an increase in ADHD symptom severity. Symptom severity was more likely to increase in subjects with a negative school outcome at baseline (vs. less negative school outcome). The effect of baseline parental occupation on ADHD symptom severity was less clear.

Psychoeducation at baseline was identified as a factor associated with an increase in ADHD symptom severity, which may be due to unmeasured confounding factors (i.e., variability in administration of psychoeducation sessions). Conversely, this outcome could be related to an earlier onset and to persistent ADHD symptoms, as European guidelines recommend beginning ADHD treatment with nonpharmacotherapy before initiating pharmacotherapy treatment. Similarly, ADORE investigators found that subjects initiated on psychotherapy and those who added psychotherapy to existing pharmacotherapy had a significant worsening of symptoms; this effect was most evident for psychoeducation counseling. Psychoeducation may have a deleterious effect if administered prior to a subject being stabilized on pharmacotherapy (Falissard et al. [@CR8]). Details about the type of psychoeducation were not captured in this study, and the relative proportion of patients who received psychoeducation was small; future studies are needed to clarify this finding.

A secondary analysis identified parental work status at baseline as a significant factor, with symptom severity being more likely to improve in subjects whose parents worked part-time; this could reflect these parents having greater ability to provide additional support to ensure medication compliance and be involved in nonpharmacotherapeutic interventions.

When factors associated with the most stringent criteria of relapse (i.e., an increase of 50 % or greater on the ADHDRS total score and an increase in the CGI-ADHD-S score of at least 2 points) were examined, relapse was more likely to occur in subjects who received psychoeducation and subjects with higher baseline ADHDRS total scores. These two factors were most consistently associated with relapse, regardless of the definition. Worse baseline school outcomes, prior family history of ADHD, and presence of certain psychiatric comorbidities were associated with relapse only when it was measured based on the CGI-ADHD-S. Analysis of factors associated with stability showed that subjects who entered the study on stimulants were less likely to maintain their initial response than those who entered the study on atomoxetine; subjects with higher baseline ADHDRS total scores were less likely to maintain their initial response. The overall relapse rates were much lower than in the initial phase of the relapse prevention trial of atomoxetine (Michelson et al. [@CR14]), possibly due to the longer response period required for entry into the AUTOR study. The observed relapse rates during the continuation period of the relapse prevention trial of atomoxetine (Buitelaar et al. [@CR5]) are comparable to those observed in AUTOR.

Additional secondary analyses showed that subjects who entered the study on stimulants reported significantly lower QoL, as measured by the CHIP-CE PRF than subjects who entered the study on atomoxetine over 2 years. This difference was most noted in the satisfaction and comfort domains. Among treatment-naïve patients randomized to treatment with atomoxetine versus other ADHD pharmacotherapy (comprised mostly of patients taking methylphenidate), atomoxetine-treated patients had significantly lower improvement on the CHIP-CE achievement domain at 6 months, but there was no significant difference between treatments at 12 months in this domain (Fuentes et al. [@CR9]). The CHIP-CE total score was not computed by Fuentes et al. The difference in their finding of improvement in CHIP-CE domain scores for the other ADHD pharmacotherapy may be due to a difference in study population, as they examined patients who were naïve to treatment and as our study was comprised of 3- to 8-month treatment responders. The continued improvement in QoL for patients initiated on atomoxetine differs slightly from the findings of the relapse prevention trial (Michelson et al. [@CR14]) in which this outcome was measured with the Child Health Questionnaire. These investigators found that under blinded conditions, maintenance of treatment with atomoxetine was associated with significantly less worsening of QoL than was removal of treatment.

Subjects who entered as responders to stimulants had greater investigator-perceived difficulties in the morning, during school, during homework, over the entire day, and in the evening as measured by the GIPD when compared with subjects who entered as responders to atomoxetine.

Limitations {#Sec18}
-----------

As an observational trial, subjects were not randomized to treatment, and treatment decisions were left to the investigator and subject; thus, treatment comparisons are subject to bias and confounding. Propensity scores were used to adjust for the probability of receiving one treatment or another, depending on differences in subject baseline characteristics; however, differences between treatment groups cannot be considered causal.

The study enrolled subjects who had responded to an initial 3--8 months of treatment with ADHD medication; therefore, the results generalize to that population rather than to all treated ADHD subjects. Additionally, patients were recruited within practices where they were treated; thus, the physician population reflects the real-world treatment patterns for ADHD in these European countries. The majority of subjects were recruited from Italy, Romania, and Greece. and the pattern of allocation to treatment reflects the timing of medication availability in those regions; therefore, factors associated with ADHD worsening are driven by the cultural, social, and economic factors of those countries during that period.

The AEs conclusions are limited because subjects had been on the same therapy for 3--8 months, which led to a lower rate of AEs overall than would be expected in patients who initiated on pharmacotherapy. Additionally, information was solicited only for specific events common with these treatments. AUTOR was not designed to characterize long-term tolerability with these medications.

In conclusion, in this observational study of more than 700 European children and adolescents with ADHD who were 3- to 8-month responders to their first pharmacotherapy, worsening of symptoms was associated with the initial use of psychoeducation, parental occupation, and poorer school outcomes, but not to initial treatment administered; however, having achieved treatment response for a 3- to 8-month period on atomoxetine was associated with improved QoL and ADHD symptom stability. AUTOR extends the ADHD relapse prevention studies by characterizing the performance of pharmacotherapy for responders in a naturalistic setting.
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